ASCO26: Toni Choueiri, MD, KEYNOTE-654 - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.

  • July 1, 2026

Share

Objective:

To evaluate the predictive capability of ctDNA assays in renal cell carcinoma patients treated with adjuvant pembrolizumab in the KEYNOTE-564 trial.

Approach:
  • Study Overview: Analysis of ctDNA status in participants of the KEYNOTE-564 trial to assess its predictive capability.
Key Findings:
  • ctDNA+ status was associated with worse disease-free outcomes.
  • Sensitivity of the ctDNA assay was low.
Interpretation:

The findings indicate limitations in the predictive capability of ctDNA assays for this patient population.

Conclusion:

The study highlights the need for improved predictive tools in renal cell carcinoma treatment.

Original Source(s)

ASCO26: Toni Choueiri, MD, KEYNOTE-654

  • July 1, 2026

Related Content

Dana-Farber Research News 04.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 1 - 15.

  • by

  • April 1, 2026

  • 37 min
Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group

Bioinformatics Investigations Uncover the Involvement of RIPK1 in Clear Cell Renal Cell Carcinoma